|, ASCR, AltPrP, CD230, CJD, GSS, KURU, PRIP, PrP, PrP27-30, PrP33-35C, PrPc, p27-30, prion protein|
PRNP (PRioN Protein) is the human gene encoding for the major prion protein PrP (for prion protein), also known as CD230 (cluster of differentiation 230). Expression of the protein is most predominant in the nervous system but occurs in many other tissues throughout the body.
The protein can exist in multiple isoforms, the normal PrPC, and as Protease resistance PrPRes like the disease-causing PrPSc(scrapie) and an isoform located in mitochondria. The misfolded version PrPSc is associated with a variety of cognitive disorders and neurodegenerative diseases such as bovine spongiform encephalopathy, chronic wasting disease, Creutzfeldt–Jakob disease, fatal familial insomnia, feline spongiform encephalopathy, Gerstmann–Sträussler–Scheinker syndrome, kuru, scrapie, transmissible mink encephalopathy, ungulate spongiform encephalopathy, and variant Creutzfeldt–Jakob disease.
- 1 Gene
- 2 Structure
- 3 Function
- 4 Diseases caused by PrP misfolding
- 5 Interactions
- 6 References
- 7 External links
PrP is highly conserved through mammals, lending credence to application of conclusions from test animals such as mice. Comparison between primates is especially similar, ranging from 92.9-99.6% similarity in amino acid sequences. The human protein structure consists of a globular domain with three α-helices and a two-strand antiparallel β-sheet, an NH2-terminal tail, and a short COOH-terminal tail. A glycophosphatidylinositol (GPI) membrane anchor at the COOH-terminal tethers PrP to cell membranes, and this proves to be integral to the transmission of conformational change; secreted PrP lacking the anchor component is unaffected by the infectious isoform.
The primary sequence of PrP is 253 amino acids long before post-translational modification. Signal sequences in the amino- and carboxy- terminal ends are removed posttranslationally, resulting in a mature length of 208 amino acids. For human and golden hamster PrP, two glycosylated sites exist on helices 2 and 3 at Asn181 and Asn197. Murine PrP has glycosylation sites as Asn180 and Asn196. A disulfide bond exists between Cys179 of the second helix and Cys214 of the third helix (human PrPC numbering).
The mechanism for conformational conversion to the scrapie isoform is speculated to be an elusive ligand-protein, but, so far, no such compound has been identified. However, a large body of research has developed on candidates and their interaction with the PrPC.
Copper, zinc, manganese, and nickel are confirmed PrP ligands that bind to its octarepeat region. Ligand binding causes a conformational change with unknown effect. Heavy metal binding at PrP has been linked to resistance to oxidative stress arising from heavy metal toxicity.
PrPC (normal cellular) isoform
Although the precise function of PrP is not yet known, it is possibly involved in the transport of ionic copper to cells from the surrounding environment. Researchers have also proposed roles for PrP in cell signaling or in the formation of synapses. PrPC attaches to the outer surface of the cell membrane by a glycosylphosphatidylinositol anchor at its C-terminal Ser231.
Prion protein contains 5 amino-terminal octapeptide repeats with sequence PHGGGWGQ. This is thought to generate a copper-binding domain via nitrogen atoms in the histidine imidazole side-chains and deprotonated amide nitrogens from the 2nd and 3rd glycines in the repeat. The ability to bind copper is, therefore, pH-dependent. NMR shows copper binding results in a conformational change at the N-terminus.
PrPSc (scrapie) isoform
PrPSc is a conformational isoform of PrPC, but this orientation tends to accumulate in compact, protease-resistant aggregates within neural tissue. The abnormal PrPSc isoform has a different secondary and tertiary structure from PrPC, but identical primary sequence. Circular dichroism shows that normal PrPC had 43% alpha helical and 3% beta sheet content, whereas PrPSc was only 30% alpha helix and 43% beta sheet. This refolding renders the PrPSc isoform extremely resistant to proteolysis.
The propagation of PrPSc is a topic of great interest, as its accumulation is a pathological cause of neurodegeneration. Based on the progressive nature of spongiform encephalopathies, the predominant hypothesis posits that the change from normal PrPC is caused by the presence and interaction with PrPSc. Strong support for this is taken from studies in which PRNP-knockout mice are resistant to the introduction of PrPSc. Despite widespread acceptance of the conformation conversion hypothesis, some studies mitigate claims for a direct link between PrPSc and cytotoxicity.
Polymorphisms at sites 136, 154, and 171 are associated with varying susceptibility to scrapie. Polymorphisms of the PrP-VRQ form and PrP-ARQ form are associated with increased susceptibility, whereas PrP-ARR is associated with resistance.
The National Scrapie Plan aims to breed out these scrapie polymorphisms by increasing the frequency of the resistant allele. However, PrP-ARR polymorphisms are susceptible to atypical scrapie, so this may prove unfruitful.
The strong association to neurodegenerative diseases raises many questions of the function of PrP in the brain. A common approach is using PrP-knockout and transgenic mice to investigate deficiencies and differences. Initial attempts produced two strains of PrP-null mice that shows no physiological or developmental differences when subjected to an array of tests. However, more recent strains have shown significant cognitive abnormalities.
As the null mice age, a marked loss of Purkinje cells in the cerebellum results in decreased motor coordination. However, this effect is not a direct result of PrP’s absence, and rather arises from increased Doppel gene expression. Other observed differences include reduced stress response and increased exploration of novel environments.
Circadian rhythm is altered in null mice. Fatal familial insomnia is thought to be the result of a point mutation in PRNP at codon 178, which corroborates PrP’s involvement in sleep-wake cycles. In addition, circadian regulation has been demonstrated in PrP mRNA, which cycles regularly with day-night.
While null mice exhibit normal learning ability and short-term memory, long-term memory consolidation deficits have been demonstrated. As with ataxia, however, this is attributable to Doppel gene expression. However, spatial learning, a predominantly hippocampal-function, is decreased in the null mice and can be recovered with the reinstatement of PrP in neurons; this indicates that loss of PrP function is the cause. The interaction of hippocampal PrP with laminin (LN) is pivotal in memory processing and is likely modulated by the kinases PKA and ERK1/2.
Further support for PrP’s role in memory formation is derived from several population studies. A test of healthy young humans showed increased long-term memory ability associated with an MM or MV genotype when compared to VV. Down Syndrome patients with a single valine substitution have been linked to earlier cognitive decline. Several polymorphisms in PRNP have been linked with cognitive impairment in the elderly as well as earlier cognitive decline. All of these studies investigated differences in codon 129, indicating its importance in the overall functionality of PrP, in particular with regard to memory.
Neurons and synapses
PrP is present in both the pre- and post-synaptic compartments, with the greatest concentration in the pre-synaptic portion. Considering this and PrP’s suite of behavioral influences, the neural cell functions and interactions are of particular interest. Based on the copper ligand, one proposed function casts PrP as a copper buffer for the synaptic cleft. In this role, the protein could serve as either a copper homeostasis mechanism, a calcium modulator, or a sensor for copper or oxidative stress. Loss of PrP function has been linked to long-term potentiation (LTP). This effect can be positive or negative and is due to changes in neuronal excitability and synaptic transmission in the hippocampus.
Some research indicates PrP involvement in neuronal development, differentiation, and neurite outgrowth. The PrP-activated signal transduction pathway is associated with axon and dendritic outgrowth with a series of kinases.
Though most attention is focused on PrP’s presence in the nervous system, it is also abundant in immune system tissue. PrP immune cells include haematopoietic stem cells, mature lymphoid and myeloid compartments, and certain lymphocytes; also, it has been detected in natural killer cells, platelets, and monocytes. T cell activation is accompanied by a strong up-regulation of PrP, though it is not requisite. The lack of immuno-response to transmissible spongiform encephalopathies (TSE), neurodegenerative diseases caused by prions, could stem from the tolerance for PrPSc.
Muscles, liver, and pituitary
PrP-null mice provide clues to a role in muscular physiology when subjected to a forced swimming test, which showed reduced locomotor activity. Ageing mice with an overexpression of PRNP showed significant degradation of muscle tissue.
Though present, very low levels of PrP exist in the liver and could be associated with liver fibrosis. Presence in the pituitary has been shown to affect neuroendrocrine function in amphibians, but little is known concerning mammalian pituitary PrP.
Varying expression of PrP through the cell cycle has led to speculation on involvement in development. A wide range of studies has been conducted investigating the role in cell proliferation, differentiation, death, and survival. Engagement of PrP has been linked to activation of signal transduction.
Modulation of signal transduction pathways has been demonstrated in cross-linking with antibodies and ligand-binding (hop/STI1 or copper). Given the diversity of interactions, effects, and distribution, PrP has been proposed as dynamic surface protein functioning in signaling pathways. Specific sites along the protein bind other proteins, biomolecules, and metals. These interfaces allow specific sets of cells to communicate based on level of expression and the surrounding microenvironment. The anchoring on a GPI raft in the lipid bilayer supports claims of an extracellular scaffolding function.
Diseases caused by PrP misfolding
- Creutzfeldt–Jakob disease - glutamic acid-200 is replaced by lysine while valine is present at amino acid 129
- Gerstmann-Sträussler-Scheinker syndrome - usually a change in codon 102 from proline to leucine
- fatal familial insomnia - aspartic acid-178 is replaced by asparagine while methionine is present at amino acid 129
The conversion of PrPC to PrPSc conformation is the mechanism of transmission of fatal, neurodegenerative transmissible spongiform encephalopathies (TSE). This can arise from genetic factors, infection from external source, or spontaneously for reasons unknown. Accumulation of PrPSc corresponds with progression of neurodegeneration and is the proposed cause. Some PRNP mutations lead to a change in single amino acids (the building-blocks of proteins) in the prion protein. Others insert additional amino acids into the protein or cause an abnormally short protein to be made. These mutations cause the cell to make prion proteins with an abnormal structure. The abnormal protein PrPSc accumulates in the brain and destroys nerve cells, which leads to the mental and behavioral features of prion diseases.
Several other changes in the PRNP gene (called polymorphisms) do not cause prion diseases but may affect a person's risk of developing these diseases or alter the course of the disorders. An allele that codes for a PRNP variant, G127V, provides resistance to Kuru.
In addition, some prion diseases can be transmitted from external sources of PrPSc.
- Scrapie - fatal neurodegenerative disease in sheep, not transmissible to humans
- Bovine spongiform encephalopathy (mad-cow disease) - fatal neurodegenerative disease in cows, which can be transmitted to humans by ingestion of brain, spinal, or digestive tract tissue of an infected cow
- Kuru - TSE in humans, transmitted via funerary cannibalism. Generally, affected family members were given, by tradition, parts of the central nervous system according to ritual when consuming deceased family members.
PrPC protein is one of several cellular receptors of soluble amyloid beta (Aβ) oligomers, which are canonically implicated in causing Alzheimer’s disease. These oligomers are composed smaller Aβ plaques, and are the most damaging to the integrity of a neuron. The precise mechanism of soluble Aβ oligomers directly inducing neurotoxicity is unknown, and experimental deletion of PRNP in animals has yielded several conflicting findings. When Aβ oligomers were injected into the cerebral ventricles of a mouse model of Alzheimer’s, PRNP deletion did not offer protection, only anti-PrPC antibodies prevented long-term memory and spatial learning deficits. This would suggest either an unequal relation between PRNP and Aβ oligomer-mediated neurodegeneration or a site-specific relational significance. In the case of direct injection of Aβ oligomers into the hippocampus, PRNP-knockout mice were found to be indistinguishable from control with respect to both neuronal death rates and measurements of synaptic plasticity. It was further found that Aβ-oligomers bind to PrPC at the postsynaptic density, indirectly overactivating the NMDA receptor via the Fyn enzyme, resulting in excitotoxicity. Soluble Aβ oligomers also bind to PrPC at the dendritic spines, forming a complex with Fyn and excessively activating tau, another protein implicated in Alzheimer’s. As the gene FYN codes for the enzyme Fyn, FYN-knockout mice display neither excitotoxic events nor dendritic spine shrinkage when injected with Aβ oligomers. In mammals, the full functional significance of PRNP remains unclear, as PRNP deletion has been prophylactically implemented by the cattle industry without apparent harm. In mice, this same deletion phenotypically varies between Alzheimer’s mouse lines, as hAPPJ20 mice and TgCRND8 mice show a slight increase in epileptic activity, contributing to conflicting results when examining Alzheimer’s survival rates. Of note, the deletion of PRNP in both APPswe and SEN1dE9, two other transgenic models of Alzheimer’s, attenuated the epilepsy-induced death phenotype seen in a subset of these animals. Taken collectively, recent evidence suggests PRNP may be important for conducing the neurotoxic effects of soluble Aβ-oligomers and the emergent disease state of Alzheimer’s.
In humans, the Methionine/Valine polymorphism at codon 129 of PRNP (rs1799990) is most closely associated with Alzheimer’s disease. Variant V allele carriers (VV and MV) show a 13% decreased risk with respect to developing Alzheimer’s compared to the methionine homozygote (MM). However, the protective effects of variant V carriers have been found exclusively in Caucasians. The decreased risk in V allele carriers is further limited to late-onset Alzheimer’s disease only (≥ 65 years). PRNP can also functionally interact with polymorphisms in two other genes implicated in Alzheimer’s, PSEN1 and APOE, to compound risk for both Alzheimer’s and sporadic Creutzfeldt–Jakob disease. A point mutation on codon 102 of PRNP at least in part contributed to three separate patients’ atypical frontotemporal dementia within the same family, suggesting a new phenotype for Gerstmann-Straussler-Scheinker syndrome. The same study proposed sequencing PRNP in cases of ambiguously diagnosed dementia, as the various forms of dementia can prove challenging to differentially diagnose.
- GRCh38: Ensembl release 89: ENSG00000171867 - Ensembl, May 2017
- GRCm38: Ensembl release 89: ENSMUSG00000079037 - Ensembl, May 2017
- "Human PubMed Reference:".
- "Mouse PubMed Reference:".
- Kretzschmar HA, Stowring LE, Westaway D, Stubblebine WH, Prusiner SB, Dearmond SJ (August 1986). "Molecular cloning of a human prion protein cDNA". DNA. 5 (4): 315–24. PMID 3755672. doi:10.1089/dna.1986.5.315.
- Sparkes RS, Simon M, Cohn VH, Fournier RE, Lem J, Klisak I, Heinzmann C, Blatt C, Lucero M, Mohandas T (October 1986). "Assignment of the human and mouse prion protein genes to homologous chromosomes". Proc. Natl. Acad. Sci. U.S.A. 83 (19): 7358–62. PMC . PMID 3094007. doi:10.1073/pnas.83.19.7358.
- Liao YC, Lebo RV, Clawson GA, Smuckler EA (July 1986). "Human prion protein cDNA: molecular cloning, chromosomal mapping, and biological implications". Science. 233 (4761): 364–7. PMID 3014653. doi:10.1126/science.3014653.
- Robakis NK, Devine-Gage EA, Jenkins EC, Kascsak RJ, Brown WT, Krawczun MS, Silverman WP (October 1986). "Localization of a human gene homologous to the PrP gene on the p arm of chromosome 20 and detection of PrP-related antigens in normal human brain". Biochem. Biophys. Res. Commun. 140 (2): 758–65. PMID 2877664. doi:10.1016/0006-291X(86)90796-5.
- Prusiner SB (2001). "Shattuck lecture--neurodegenerative diseases and prions". N Engl J Med. 344 (20): 1516–26. PMID 11357156. doi:10.1056/NEJM200105173442006.
- Weissmann C (2004). "The state of the prion". Nat Rev Microbiol. 2 (11): 861–71. PMID 15494743. doi:10.1038/nrmicro1025.
- Zomosa-Signoret V, Arnaud JD, Fontes P, Alvarez-Martinez MT, Liautard JP (2008). "Physiological role of the cellular prion protein". Vet. Res. 39 (4): 9. PMID 18073096. doi:10.1051/vetres:2007048.
- Damberger FF, Christen B, Pérez DR, Hornemann S, Wüthrich K (October 2011). "Cellular prion protein conformation and function". Proc. Natl. Acad. Sci. U.S.A. 108 (42): 17308–13. PMC . PMID 21987789. doi:10.1073/pnas.1106325108.
- Schätzl HM, Da Costa M, Taylor L, Cohen FE, Prusiner SB (January 1995). "Prion protein gene variation among primates". J. Mol. Biol. 245 (4): 362–74. PMID 7837269. doi:10.1006/jmbi.1994.0030.
- Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, Raymond L, Favara C, Baron G, Priola S, Caughey B, Masliah E, Oldstone M (June 2005). "Anchorless prion protein results in infectious amyloid disease without clinical scrapie". Science. 308 (5727): 1435–9. PMID 15933194. doi:10.1126/science.1110837.
- Barrette I, Poisson G, Gendron P, Major F (2001). "Pseudoknots in prion protein mRNAs confirmed by comparative sequence analysis and pattern searching". Nucleic Acids Res. 29 (3): 753–758. PMC . PMID 11160898. doi:10.1093/nar/29.3.753.
- Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR (April 2008). "Physiology of the prion protein". Physiol. Rev. 88 (2): 673–728. PMID 18391177. doi:10.1152/physrev.00007.2007.
- Prčina M, Kontseková E, Novák M (2015). "Prion protein prevents heavy metals overloading of cells and thus protects them against their toxicity". Acta Virol. 59 (2): 179–84. PMID 26104335. doi:10.4149/av_2015_02_179.
- Brown DR, Clive C, Haswell SJ (January 2001). "Antioxidant activity related to copper binding of native prion protein". J. Neurochem. 76 (1): 69–76. PMID 11145979. doi:10.1046/j.1471-4159.2001.00009.x.
- Kanaani Prusiner Diacovo Baekkeskov and Legname, , Journal of Neurochemistry, 2005
- Ross CA, Poirier MA (July 2004). "Protein aggregation and neurodegenerative disease". Nat. Med. 10 Suppl: S10–7. PMID 15272267. doi:10.1038/nm1066.
- Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE (December 1993). "Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins". Proc. Natl. Acad. Sci. U.S.A. 90 (23): 10962–6. PMC . PMID 7902575. doi:10.1073/pnas.90.23.10962.
- Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR, Collinge J (February 2011). "Prion propagation and toxicity in vivo occur in two distinct mechanistic phases". Nature. 470 (7335): 540–2. PMID 21350487. doi:10.1038/nature09768.
- Büeler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C (July 1993). "Mice devoid of PrP are resistant to scrapie". Cell. 73 (7): 1339–47. PMID 8100741. doi:10.1016/0092-8674(93)90360-3.
- Aguzzi A, Baumann F, Bremer J (2008). "The prion's elusive reason for being". Annu. Rev. Neurosci. 31: 439–77. PMID 18558863. doi:10.1146/annurev.neuro.31.060407.125620.
- Weissmann C, Flechsig E (2003). "PrP knock-out and PrP transgenic mice in prion research". Br. Med. Bull. 66: 43–60. PMID 14522848. doi:10.1093/bmb/66.1.43.
- Katamine S, Nishida N, Sugimoto T, Noda T, Sakaguchi S, Shigematsu K, Kataoka Y, Nakatani A, Hasegawa S, Moriuchi R, Miyamoto T (December 1998). "Impaired motor coordination in mice lacking prion protein". Cell. Mol. Neurobiol. 18 (6): 731–42. PMID 9876879. doi:10.1023/A:1020234321879.
- Nico PB, de-Paris F, Vinadé ER, Amaral OB, Rockenbach I, Soares BL, Guarnieri R, Wichert-Ana L, Calvo F, Walz R, Izquierdo I, Sakamoto AC, Brentani R, Martins VR, Bianchin MM (July 2005). "Altered behavioural response to acute stress in mice lacking cellular prion protein". Behav. Brain Res. 162 (2): 173–81. PMID 15970215. doi:10.1016/j.bbr.2005.02.003.
- Roesler R, Walz R, Quevedo J, de-Paris F, Zanata SM, Graner E, Izquierdo I, Martins VR, Brentani RR (August 1999). "Normal inhibitory avoidance learning and anxiety, but increased locomotor activity in mice devoid of PrP(C)". Brain Res. Mol. Brain Res. 71 (2): 349–53. PMID 10521590. doi:10.1016/S0169-328X(99)00193-X.
- Medori R, Tritschler HJ, LeBlanc A, Villare F, Manetto V, Chen HY, Xue R, Leal S, Montagna P, Cortelli P (February 1992). "Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene". N. Engl. J. Med. 326 (7): 444–9. PMID 1346338. doi:10.1056/NEJM199202133260704.
- Cagampang FR, Whatley SA, Mitchell AL, Powell JF, Campbell IC, Coen CW (1999). "Circadian regulation of prion protein messenger RNA in the rat forebrain: a widespread and synchronous rhythm". Neuroscience. 91 (4): 1201–4. PMID 10391428. doi:10.1016/S0306-4522(99)00092-5.
- Criado JR, Sánchez-Alavez M, Conti B, Giacchino JL, Wills DN, Henriksen SJ, Race R, Manson JC, Chesebro B, Oldstone MB (2005). "Mice devoid of prion protein have cognitive deficits that are rescued by reconstitution of PrP in neurons". Neurobiol. Dis. 19 (1-2): 255–65. PMID 15837581. doi:10.1016/j.nbd.2005.01.001.
- Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, Chiesa R, Gobbi M, Salmona M, Forloni G (February 2010). "Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein". Proc. Natl. Acad. Sci. U.S.A. 107 (5): 2295–300. PMC . PMID 20133875. doi:10.1073/pnas.0911829107.
- Coitinho AS, Freitas AR, Lopes MH, Hajj GN, Roesler R, Walz R, Rossato JI, Cammarota M, Izquierdo I, Martins VR, Brentani RR (December 2006). "The interaction between prion protein and laminin modulates memory consolidation". Eur. J. Neurosci. 24 (11): 3255–64. PMID 17156386. doi:10.1111/j.1460-9568.2006.05156.x.
- Shorter J, Lindquist S (June 2005). "Prions as adaptive conduits of memory and inheritance". Nat. Rev. Genet. 6 (6): 435–50. PMID 15931169. doi:10.1038/nrg1616.
- Papassotiropoulos A, Wollmer MA, Aguzzi A, Hock C, Nitsch RM, de Quervain DJ (August 2005). "The prion gene is associated with human long-term memory". Hum. Mol. Genet. 14 (15): 2241–6. PMID 15987701. doi:10.1093/hmg/ddi228.
- Del Bo R, Comi GP, Giorda R, Crimi M, Locatelli F, Martinelli-Boneschi F, Pozzoli U, Castelli E, Bresolin N, Scarlato G (June 2003). "The 129 codon polymorphism of the prion protein gene influences earlier cognitive performance in Down syndrome subjects". J. Neurol. 250 (6): 688–92. PMID 12796830. doi:10.1007/s00415-003-1057-5.
- Berr C, Richard F, Dufouil C, Amant C, Alperovitch A, Amouyel P (September 1998). "Polymorphism of the prion protein is associated with cognitive impairment in the elderly: the EVA study". Neurology. 51 (3): 734–7. PMID 9748018. doi:10.1212/wnl.51.3.734.
- Croes EA, Dermaut B, Houwing-Duistermaat JJ, Van den Broeck M, Cruts M, Breteler MM, Hofman A, van Broeckhoven C, van Duijn CM (August 2003). "Early cognitive decline is associated with prion protein codon 129 polymorphism". Ann. Neurol. 54 (2): 275–6. PMID 12891686. doi:10.1002/ana.10658.
- Kachiwala SJ, Harris SE, Wright AF, Hayward C, Starr JM, Whalley LJ, Deary IJ (September 2005). "Genetic influences on oxidative stress and their association with normal cognitive ageing". Neurosci. Lett. 386 (2): 116–20. PMID 16023289. doi:10.1016/j.neulet.2005.05.067.
- Herms J, Tings T, Gall S, Madlung A, Giese A, Siebert H, Schürmann P, Windl O, Brose N, Kretzschmar H (October 1999). "Evidence of presynaptic location and function of the prion protein". J. Neurosci. 19 (20): 8866–75. PMID 10516306.
- Kardos J, Kovács I, Hajós F, Kálmán M, Simonyi M (August 1989). "Nerve endings from rat brain tissue release copper upon depolarization. A possible role in regulating neuronal excitability". Neurosci. Lett. 103 (2): 139–44. PMID 2549468. doi:10.1016/0304-3940(89)90565-X.
- Bailey CH, Kandel ER, Si K (September 2004). "The persistence of long-term memory: a molecular approach to self-sustaining changes in learning-induced synaptic growth". Neuron. 44 (1): 49–57. PMID 15450159. doi:10.1016/j.neuron.2004.09.017.
- Barco A, Bailey CH, Kandel ER (June 2006). "Common molecular mechanisms in explicit and implicit memory". J. Neurochem. 97 (6): 1520–33. PMID 16805766. doi:10.1111/j.1471-4159.2006.03870.x.
- Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (February 2009). "Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers". Nature. 457 (7233): 1128–32. PMC . PMID 19242475. doi:10.1038/nature07761.
- Isaacs JD, Jackson GS, Altmann DM (October 2006). "The role of the cellular prion protein in the immune system". Clin. Exp. Immunol. 146 (1): 1–8. PMC . PMID 16968391. doi:10.1111/j.1365-2249.2006.03194.x.
- Castilla J, Hetz C, Soto C (2004). "Molecular mechanisms of neurotoxicity of pathological prion protein". Curr Mol Med. 4 (4): 397–403. PMID 15354870. doi:10.2174/1566524043360654.
- Kovács GG, Trabattoni G, Hainfellner JA, Ironside JW, Knight RS, Budka H (2002). "Mutations of the prion protein gene phenotypic spectrum". J Neurol. 249 (11): 1567–82. PMID 12420099. doi:10.1007/s00415-002-0896-9.
- Collins S, McLean CA, Masters CL (2001). "Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, and kuru: a review of these less common human transmissible spongiform encephalopathies". J Clin Neurosci. 8 (5): 387–97. PMID 11535002. doi:10.1054/jocn.2001.0919.
- Montagna P, Gambetti P, Cortelli P, Lugaresi E (2003). "Familial and sporadic fatal insomnia". Lancet Neurol. 2 (3): 167–76. PMID 12849238. doi:10.1016/S1474-4422(03)00323-5.
- Medical Research Council (UK) (November 21, 2009). "Brain Disease 'Resistance Gene' Evolves in Papua New Guinea Community; Could Offer Insights Into CJD". Science Daily (online). Science News. Retrieved 2009-11-22.
- Mead S, Whitfield J, Poulter M, Shah P, Uphill J, Campbell T, Al-Dujaily H, Hummerich H, Beck J, Mein CA, Verzilli C, Whittaker J, Alpers MP, Collinge J (2009). "A Novel Protective Prion Protein Variant that Colocalizes with Kuru Exposure". The New England Journal of Medicine. 361 (21): 2056–2065. PMID 19923577. doi:10.1056/NEJMoa0809716.
- Hwang D, Lee IY, Yoo H, Gehlenborg N, Cho JH, Petritis B, Baxter D, Pitstick R, Young R, Spicer D, Price ND, Hohmann JG, Dearmond SJ, Carlson GA, Hood LE (2009). "A systems approach to prion disease". Mol. Syst. Biol. 5 (1): 252. PMC . PMID 19308092. doi:10.1038/msb.2009.10.
- Laurén J (2014). "Cellular prion protein as a therapeutic target in Alzheimer's disease". Journal of Alzheimer's Disease. 38 (2): 227–44. PMID 23948943. doi:10.3233/JAD-130950.
- Zhou J, Liu B (May 2013). "Alzheimer's disease and prion protein". Intractable & Rare Diseases Research. 2 (2): 35–44. PMC . PMID 25343100. doi:10.5582/irdr.2013.v2.2.35.
- Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (Feb 2009). "Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers". Nature. 457 (7233): 1128–32. PMC . PMID 19242475. doi:10.1038/nature07761.
- He J, Li X, Yang J, Huang J, Fu X, Zhang Y, Fan H (Mar 2013). "The association between the methionine/valine (M/V) polymorphism (rs1799990) in the PRNP gene and the risk of Alzheimer disease: an update by meta-analysis". Journal of the Neurological Sciences. 326 (1-2): 89–95. PMID 23399523. doi:10.1016/j.jns.2013.01.020.
- Giovagnoli AR, Di Fede G, Aresi A, Reati F, Rossi G, Tagliavini F (Dec 2008). "Atypical frontotemporal dementia as a new clinical phenotype of Gerstmann-Straussler-Scheinker disease with the PrP-P102L mutation. Description of a previously unreported Italian family". Neurological Sciences. 29 (6): 405–10. PMID 19030774. doi:10.1007/s10072-008-1025-z.
- Americo TA, Chiarini LB, Linden R (June 2007). "Signaling induced by hop/STI-1 depends on endocytosis". Biochem. Biophys. Res. Commun. 358 (2): 620–5. PMID 17498662. doi:10.1016/j.bbrc.2007.04.202.
- Zanata SM, Lopes MH, Mercadante AF, Hajj GN, Chiarini LB, Nomizo R, Freitas AR, Cabral AL, Lee KS, Juliano MA, de Oliveira E, Jachieri SG, Burlingame A, Huang L, Linden R, Brentani RR, Martins VR (Jul 2002). "Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection". EMBO J. 21 (13): 3307–16. PMC . PMID 12093732. doi:10.1093/emboj/cdf325.
- PRNP (PrP) gene at GeneCard
- PRNP protein, human at the US National Library of Medicine Medical Subject Headings (MeSH)
- Susan Lindquist's seminars: "The Surprising World of Prion Biology"